Table 3.
Results of pairwise and network meta-analysis for functional improvement in different follow-ups
| At 1 st month | CS | -0.52 (-1.18 to 0.14) | -0.94 (-2.02 to 0.30) | -1.11 (-2.04 to -0.24) |
| -0.64 (-1.25 to -0.03) | AB | 0.24 (-0.99 to 1.55) | -0.18 (-1.93 to 1.67) | |
| -0.87 (-1.66 to -0.12) | -0.24 (-1.06 to 0.62) | PL | -0.09 (-1.24 to 1.01) | |
| -1.04 (-1.74 to -0.37) | -0.41 (-1.21 to 0.41) | -0.17 (-0.97 to 0.63) | PRP | |
| At 3 rd month | PRP | 0.19 (-1.12 to 1.46) | -0.23 (-1.58 to 1.12) | 0.84 (-1.71 to -0.02) |
| -0.06 (-0.84 to 0.66) | AB | 0.11 (-1.24 to 1.52) | -0.67 (-1.56 to 0.15) | |
| -0.29 (-1.27 to 0.65) | -0.23 (-1.20 to 0.76) | PL | -0.04 (-1.39 to 1.29) | |
| -0.77 (-1.44 to -0.16) | -0.71 (-1.36 to -0.08) | -0.48 (-1.45 to 0.44) | CS | |
| At 6 th month | PRP | 0.12 (-1.24 to 1.48) | 0.38 (-0.04 to 0.91) | -1.13 (-1.76 to -0.63) |
| 0.02 (-1.04 to 1.03) | PL | -0.29 (-1.86 to 1.27) | -0.34 (-2.37 to 1.74) | |
| -0.27 (-1.23 to 0.63) | -0.29 (-1.44 to 0.78) | AB | 0.42 (0.02 to 0.73) | |
| -0.44 (-1.39 to 0.48) | -0.46 (-1.70 to 0.69) | -0.16 (-1.02 to 0.68) | CS |
Note: Treatments are ranked according to their SUCRA. The comparative therapeutic efficacies are reported as standardized mean difference with 95% credible intervals (in parentheses). The comparison between the treatments should be read from left to right. The network meta-analysis results are presented in the left lower (by comparing columns with rows), and the pairwise meta-analysis results are presented in the right upper (by comparing rows with columns).
Abbreviations: CS, corticosteroid; AB, autologous blood; PRP, platelet-rich plasma; PL, placebo